{"transactions":[{"id":2211082,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2022-07-07T20:30:28.000Z","date":"2022-07-06","kind":"sale","acquired":false,"shares":8956,"price":3.79,"value":33943.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $4.00, inclusive."}],"balance_after":530589,"source":{"system":"sec-edgar","filing":"0001209191-22-041455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122041455/doc4.xml","form_type":"4"}},{"id":2211081,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2022-07-07T20:30:28.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":3905,"price":3.51,"value":13706.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":539545,"source":{"system":"sec-edgar","filing":"0001209191-22-041455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122041455/doc4.xml","form_type":"4"}},{"id":2218098,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2022-07-01T22:55:05.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":23923,"price":3.53,"value":84448.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.41 to $3.82, inclusive."}],"balance_after":543450,"source":{"system":"sec-edgar","filing":"0001209191-22-040356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122040356/doc4.xml","form_type":"4"}},{"id":2218097,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2022-07-01T22:55:05.000Z","date":"2022-06-30","kind":"sale","acquired":false,"shares":13892,"price":3.72,"value":51678.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.81, inclusive."}],"balance_after":567373,"source":{"system":"sec-edgar","filing":"0001209191-22-040356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122040356/doc4.xml","form_type":"4"}},{"id":2218096,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2022-07-01T22:55:05.000Z","date":"2022-06-29","kind":"sale","acquired":false,"shares":12324,"price":3.81,"value":46954.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.64 to $3.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4)."}],"balance_after":581265,"source":{"system":"sec-edgar","filing":"0001209191-22-040356","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122040356/doc4.xml","form_type":"4"}},{"id":2300771,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-04-08T20:26:27.000Z","date":"2022-04-06","kind":"grant","acquired":true,"shares":40325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on April 6, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":40325,"derivative":{"exercise_price":6.52,"expiration_date":"2032-04-06","underlying":"Common Stock","underlying_shares":40325},"source":{"system":"sec-edgar","filing":"0001209191-22-023862","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122023862/doc4.xml","form_type":"4"}},{"id":2373348,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-25T21:20:09.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":80650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":80650,"derivative":{"exercise_price":5.96,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":80650},"source":{"system":"sec-edgar","filing":"0001209191-22-013163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122013163/doc4.xml","form_type":"4"}},{"id":2648882,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2021-07-01T22:32:03.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":19706,"price":21.12,"value":416190.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.81 to $21.53, inclusive."}],"balance_after":593589,"source":{"system":"sec-edgar","filing":"0001209191-21-044563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121044563/doc4.xml","form_type":"4"}},{"id":2648881,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2021-07-01T22:32:03.000Z","date":"2021-06-30","kind":"sale","acquired":false,"shares":500,"price":23.7,"value":11850.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.16 to $24.00, inclusive."}],"balance_after":613295,"source":{"system":"sec-edgar","filing":"0001209191-21-044563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121044563/doc4.xml","form_type":"4"}},{"id":2648880,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2021-07-01T22:32:03.000Z","date":"2021-06-30","kind":"sale","acquired":false,"shares":6202,"price":22.44,"value":139172.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.15 to $23.11, inclusive."}],"balance_after":613795,"source":{"system":"sec-edgar","filing":"0001209191-21-044563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121044563/doc4.xml","form_type":"4"}},{"id":2648879,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2021-07-01T22:32:03.000Z","date":"2021-06-30","kind":"sale","acquired":false,"shares":13374,"price":21.42,"value":286471.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.13 to $22.11, inclusive."}],"balance_after":619997,"source":{"system":"sec-edgar","filing":"0001209191-21-044563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121044563/doc4.xml","form_type":"4"}},{"id":2648878,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2021-07-01T22:32:03.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":300,"price":25.19,"value":7557.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.44, inclusive."}],"balance_after":633371,"source":{"system":"sec-edgar","filing":"0001209191-21-044563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121044563/doc4.xml","form_type":"4"}},{"id":2648877,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2021-07-01T22:32:03.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":3862,"price":24.46,"value":94464.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.04 to $24.95, inclusive."}],"balance_after":633671,"source":{"system":"sec-edgar","filing":"0001209191-21-044563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121044563/doc4.xml","form_type":"4"}},{"id":2648876,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2021-07-01T22:32:03.000Z","date":"2021-06-29","kind":"sale","acquired":false,"shares":35056,"price":23.74,"value":832229.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.04 to\n$24.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2), (3), (4), (5), (6), (7) and (8)."}],"balance_after":637533,"source":{"system":"sec-edgar","filing":"0001209191-21-044563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121044563/doc4.xml","form_type":"4"}},{"id":2903491,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-21T01:21:43.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":80000,"derivative":{"exercise_price":31,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-21-004572","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121004572/doc4.xml","form_type":"4"}},{"id":3020358,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Series B Preferred Stock","published_at":"2020-09-30T20:39:33.000Z","date":"2020-09-28","kind":"exercise","acquired":false,"shares":3529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3844},"source":{"system":"sec-edgar","filing":"0001209191-20-052463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052463/doc4.xml","form_type":"4"}},{"id":3020357,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2020-09-30T20:39:33.000Z","date":"2020-09-28","kind":"exercise","acquired":true,"shares":3844,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."}],"balance_after":672589,"source":{"system":"sec-edgar","filing":"0001209191-20-052463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052463/doc4.xml","form_type":"4"}},{"id":3022675,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO and Head of R&D"}}],"security":"Common Stock","published_at":"2020-09-25T21:14:44.000Z","date":"2020-09-23","kind":"grant","acquired":true,"shares":668745,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the RSU vest in 4 equal annual installments on each of June 29, 2021, June 29, 2022, June 29, 2023 and June 29, 2024, subject to the Reporting Person's continuous service as of each such vesting date"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share the Issuer's common stock."}],"balance_after":668745,"source":{"system":"sec-edgar","filing":"0001209191-20-052116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052116/doc4.xml","form_type":"4"}},{"id":3497217,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2019-06-07T16:42:25.000Z","date":"2019-06-05","kind":"tax_withholding","acquired":false,"shares":757,"price":37.31,"value":28243.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes."}],"balance_after":17479,"source":{"system":"sec-edgar","filing":"0001209191-19-035588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119035588/doc4.xml","form_type":"4"}},{"id":3526076,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-05-15T16:42:25.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events."}],"balance_after":30870,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-030040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119030040/doc4.xml","form_type":"4"}},{"id":3526075,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2019-05-15T16:42:25.000Z","date":"2019-05-13","kind":"sale","acquired":false,"shares":54,"price":37.72,"value":2036.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":18236,"source":{"system":"sec-edgar","filing":"0001209191-19-030040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119030040/doc4.xml","form_type":"4"}},{"id":3526074,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2019-05-15T16:42:25.000Z","date":"2019-05-13","kind":"sale","acquired":false,"shares":9946,"price":36.9758,"value":367761.3068,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price.  The lowest price at which shares were sold was $36.61 and the highest price at which shares were sold was $37.46.   The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":18290,"source":{"system":"sec-edgar","filing":"0001209191-19-030040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119030040/doc4.xml","form_type":"4"}},{"id":3526073,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2019-05-15T16:42:25.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":10000,"price":0.79,"value":7900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":28236,"source":{"system":"sec-edgar","filing":"0001209191-19-030040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119030040/doc4.xml","form_type":"4"}},{"id":3629090,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-27T16:32:42.000Z","date":"2019-02-25","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events."}],"balance_after":40870,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-014074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119014074/doc4.xml","form_type":"4"}},{"id":3629089,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2019-02-27T16:32:42.000Z","date":"2019-02-25","kind":"sale","acquired":false,"shares":10000,"price":30.0553,"value":300553.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $30.00 and the highest price at which shares were sold was $30.23. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":18236,"source":{"system":"sec-edgar","filing":"0001209191-19-014074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119014074/doc4.xml","form_type":"4"}},{"id":3629088,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2019-02-27T16:32:42.000Z","date":"2019-02-25","kind":"exercise","acquired":true,"shares":10000,"price":0.79,"value":7900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":28236,"source":{"system":"sec-edgar","filing":"0001209191-19-014074","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119014074/doc4.xml","form_type":"4"}},{"id":3668236,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T17:25:26.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":48750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 2.0833% of the total shares monthly, beginning February 1, 2019, with 100% of the total shares vested and exercisable on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":48750,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":48750},"source":{"system":"sec-edgar","filing":"0001209191-19-008671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119008671/doc4.xml","form_type":"4"}},{"id":3668235,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2019-02-08T17:25:26.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the issuer's Common Stock upon settlement for no consideration.  The RSUs will vest as to 2/16ths of the award on June 5, 2019, and then 1/16th of the RSUs will vest on each of September 5, December 5, March 5 and June 5 thereafter until the RSUs are fully vested, subject to the Reporting Person's provision of services to the issuer on each vesting date.  Shares of the issuer's Common Stock will be delivered to the Reporting Person following vesting."}],"balance_after":18236,"source":{"system":"sec-edgar","filing":"0001209191-19-008671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119008671/doc4.xml","form_type":"4"}},{"id":3761065,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-11-16T18:37:34.000Z","date":"2018-11-15","kind":"grant","acquired":true,"shares":736,"price":19.635,"value":14451.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and 16b-3(d)."}],"balance_after":736,"source":{"system":"sec-edgar","filing":"0001209191-18-059058","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118059058/doc4.xml","form_type":"4"}},{"id":3801451,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events."}],"balance_after":50870,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801450,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common  Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":4699,"price":35.5998,"value":167283.4602,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $35.25 and the highest price at which shares were sold was $36.17."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801449,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":4699,"price":0.79,"value":3712.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":4699,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801448,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":200,"price":36.315,"value":7263.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $36.305 and the highest price at which shares were sold was $36.325."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801447,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":200,"price":0.79,"value":158.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":200,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801446,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":3900,"price":37.8237,"value":147512.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $37.41 and the highest price at which shares were sold was $38.25."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801445,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":3900,"price":0.79,"value":3081.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":3900,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801444,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":1101,"price":38.8533,"value":42777.4833,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $38.46 and the highest price at which shares were sold was $39.43. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4 and 5 to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801443,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":1101,"price":0.79,"value":869.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":1101,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801442,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":100,"price":39.52,"value":3952.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3801441,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-10-02T19:05:05.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":100,"price":0.79,"value":79.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0001209191-18-053468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118053468/doc4.xml","form_type":"4"}},{"id":3872694,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-07-05T18:35:27.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":5011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":60870,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":5011},"source":{"system":"sec-edgar","filing":"0001209191-18-041769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118041769/doc4.xml","form_type":"4"}},{"id":3872693,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-07-05T18:35:27.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":4989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":65881,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":4989},"source":{"system":"sec-edgar","filing":"0001209191-18-041769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118041769/doc4.xml","form_type":"4"}},{"id":3872692,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Copmmon Stock","published_at":"2018-07-05T18:35:27.000Z","date":"2018-07-02","kind":"sale","acquired":false,"shares":5011,"price":38.7874,"value":194363.6614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $38.50 and the highest price at which shares were sold was $39.30."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-041769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118041769/doc4.xml","form_type":"4"}},{"id":3872691,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-07-05T18:35:27.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":5011,"price":0.79,"value":3958.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":5011,"source":{"system":"sec-edgar","filing":"0001209191-18-041769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118041769/doc4.xml","form_type":"4"}},{"id":3872690,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-07-05T18:35:27.000Z","date":"2018-07-02","kind":"sale","acquired":false,"shares":4989,"price":38.0244,"value":189703.7316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $37.465 and the highest price at which shares were sold was $38.37. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth in footnotes 2 and 3 to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-041769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118041769/doc4.xml","form_type":"4"}},{"id":3872689,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-07-05T18:35:27.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":4989,"price":0.79,"value":3941.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":4989,"source":{"system":"sec-edgar","filing":"0001209191-18-041769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118041769/doc4.xml","form_type":"4"}},{"id":3979723,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-29T20:23:26.000Z","date":"2018-03-29","kind":"exercise","acquired":false,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":70870,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-18-022169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022169/doc4.xml","form_type":"4"}},{"id":3979722,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-03-29T20:23:26.000Z","date":"2017-03-29","kind":"sale","acquired":false,"shares":7800,"price":30.025,"value":234195.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $30.00 and the highest price at which shares were sold was $30.16. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-022169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022169/doc4.xml","form_type":"4"}},{"id":3979721,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-03-29T20:23:26.000Z","date":"2018-03-29","kind":"exercise","acquired":true,"shares":7800,"price":0.79,"value":6162.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":7800,"source":{"system":"sec-edgar","filing":"0001209191-18-022169","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022169/doc4.xml","form_type":"4"}},{"id":3980899,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-28T21:12:26.000Z","date":"2018-03-27","kind":"exercise","acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":78670,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":300},"source":{"system":"sec-edgar","filing":"0001209191-18-022004","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022004/doc4.xml","form_type":"4"}},{"id":3980898,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-28T21:12:26.000Z","date":"2018-03-26","kind":"exercise","acquired":false,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":78970,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":1900},"source":{"system":"sec-edgar","filing":"0001209191-18-022004","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022004/doc4.xml","form_type":"4"}},{"id":3980897,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-03-28T21:12:26.000Z","date":"2017-03-27","kind":"sale","acquired":false,"shares":300,"price":30,"value":9000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-022004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022004/doc4.xml","form_type":"4"}},{"id":3980896,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-03-28T21:12:26.000Z","date":"2018-03-27","kind":"exercise","acquired":true,"shares":300,"price":0.79,"value":237.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":300,"source":{"system":"sec-edgar","filing":"0001209191-18-022004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022004/doc4.xml","form_type":"4"}},{"id":3980895,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-03-28T21:12:26.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":1900,"price":30,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-022004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022004/doc4.xml","form_type":"4"}},{"id":3980894,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2018-03-28T21:12:26.000Z","date":"2018-03-26","kind":"exercise","acquired":true,"shares":1900,"price":0.79,"value":1501.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":1900,"source":{"system":"sec-edgar","filing":"0001209191-18-022004","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022004/doc4.xml","form_type":"4"}},{"id":4142092,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-12-05T16:00:14.000Z","date":"2017-12-01","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":80870,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-063856","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117063856/doc4.xml","form_type":"4"}},{"id":4142091,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2017-12-05T16:00:14.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":1230,"price":28.9842,"value":35650.566,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $28.95 and the highest price at which shares were sold was $29.04."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-063856","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117063856/doc4.xml","form_type":"4"}},{"id":4142090,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2017-12-05T16:00:14.000Z","date":"2017-12-01","kind":"exercise","acquired":true,"shares":1230,"price":0.79,"value":971.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":1230,"source":{"system":"sec-edgar","filing":"0001209191-17-063856","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117063856/doc4.xml","form_type":"4"}},{"id":4142089,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2017-12-05T16:00:14.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":6770,"price":28.451,"value":192613.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $27.93 and the highest price at which shares were sold was $28.91. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-063856","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117063856/doc4.xml","form_type":"4"}},{"id":4142088,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2017-12-05T16:00:14.000Z","date":"2017-12-01","kind":"exercise","acquired":true,"shares":6770,"price":0.79,"value":5348.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":6770,"source":{"system":"sec-edgar","filing":"0001209191-17-063856","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117063856/doc4.xml","form_type":"4"}},{"id":4158266,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-11-17T17:07:39.000Z","date":"2017-11-16","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":75000,"derivative":{"exercise_price":27.39,"expiration_date":"2027-11-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-17-061546","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117061546/doc4.xml","form_type":"4"}},{"id":4219728,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-09-01T17:55:16.000Z","date":"2017-09-01","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":88870,"derivative":{"exercise_price":0.79,"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-051077","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117051077/doc4.xml","form_type":"4"}},{"id":4219727,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2017-09-01T17:55:16.000Z","date":"2017-09-01","kind":"sale","acquired":false,"shares":8000,"price":21.4351,"value":171480.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-051077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117051077/doc4.xml","form_type":"4"}},{"id":4219726,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Common Stock","published_at":"2017-09-01T17:55:16.000Z","date":"2017-09-01","kind":"exercise","acquired":true,"shares":8000,"price":0.79,"value":6320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-17-051077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117051077/doc4.xml","form_type":"4"}},{"id":4479323,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":125542,"kind":"person","name":"PRASAD SUYASH","position":1,"cik":"0001679129","reported_name":"PRASAD SUYASH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & Chief Med Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-27T18:10:46.000Z","date":"2017-01-25","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":70000,"derivative":{"exercise_price":15.26,"expiration_date":"2027-01-25","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-17-005999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117005999/doc4.xml","form_type":"4"}}]}